Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Seattle Genetics has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Genentech, a wholly owned member of the Roche Group.
Subscribe to our email newsletter
The milestone was triggered by Genentech’s submission of an investigational new drug (IND) application with the FDA for an ADC utilising Seattle Genetics’ technology for the treatment of cancer.
ADCs are empowered monoclonal antibodies that carry potent, cell-killing drugs. Seattle Genetics has developed proprietary technology employing synthetic, highly potent drugs that can be attached to antibodies through stable linker systems.
As per the terms of the ADC collaboration agreement, Genentech has rights to use Seattle Genetics’ ADC technology with monoclonal antibodies against targets selected by Genentech.
Genentech will be responsible for research, product development, manufacturing and commercialisation activities under the collaboration. Seattle Genetics will be entitled to receive fees, progress-dependent milestone payments and royalties on net sales of any resulting ADC products.
Eric Dobmeier, chief business officer of Seattle Genetics, said: “This IND submission is reflective of the continued progress by our collaborators in the development of product candidates based on our proprietary ADC technology.
“We are pleased that Genentech has advanced an ADC program using our technology towards clinical trials. We believe this further demonstrates the potential of ADCs to play an increasingly important role in the treatment of cancer and other serious diseases.”